GlassScriptPhysician profile
George Edward Mark, IV
NPI 1265516488
$311,841.18
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101K · 2020: $32K · 2021: $31K · 2022: $61K · 2023: $53K · 2024: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $43K · Travel and Lodging: $13K · Honoraria: $12K · Food and Beverage: $10K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,000 · Education: $228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $43,425.00 |
| Travel and Lodging | $13,150.87 |
| Honoraria | $11,600.00 |
| Food and Beverage | $10,475.52 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,000.00 |
| Education | $228.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $132,581.38 | 2019-2024 | Watchman Access System, Watchman Flx, Watchman |
| Abbott Laboratories | $81,659.38 | 2019-2024 | Amplatzer Amulet, Aveir, Ensite |
| Impulse Dynamics (USA) INC. | $40,030.76 | 2019-2024 | Optimizer, Optimizer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $29,306.94 | 2019-2024 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $11,701.59 | 2019-2024 | Eliquis, Camzyos |
| Biotronik INC. | $3,861.31 | 2019-2024 | Biomonitor, Acticor 7 Vr-T Dx |
| Biosense Webster, INC. | $3,747.25 | 2019-2024 | Octaray Mapping Catheter, Carto 3, Qdot Micro Catheter |
| Pfizer INC. | $3,173.97 | 2019-2023 | |
| Medical Device Business Services, INC. | $2,275.00 | 2019-2022 | |
| Atricure, INC. | $804.81 | 2019-2024 | |
| Cvrx, INC. | $456.81 | 2022-2024 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $445.40 | 2019-2024 | Xarelto |
| Amgen INC. | $216.67 | 2019-2024 | Repatha |
| Philips North America LLC | $175.96 | 2019-2021 | |
| Medtronic, INC. | $148.25 | 2022-2023 | Arctic Front Advance, Azure Xt Dr Mri Surescan, Na |
Show all 40 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Mark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.